DXY, EUR/USD, USD/JPY, GBP/USD, AUD/USD, USD/CAD
SPDR S&P 500, ISHARES MSCI EMERGING INDEX FUND, PROTEOSTASIS THERAPEUTICS, INC. - COMMON STOCK, HELIOS AND MATHESON ANALYTICS INC - COMMON STOCK, INVESCO QQQ TRUST, SERIES 1, SPDR SELECT SECTOR FUND - FINANCIAL
S&P 500, Nasdaq Composite, Dow 30, Nikkei 225, DAX Index, FTSE 100
Gold, Silver, Crude Oil, Natural Gas, Corn, Bitcoin
BTC/USD, ETH/USD, BCH/USD, XRP/USD, LTC/USD, ETC/USD
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
Gold, Brent Oil, Crude Oil, CFDs on Natural Gas, Palladium, Silver
Following a year long downtrend after management followed through with a secondary offering, my chart shows a possible cement floor at 1.80. Higher accumulation and a recent uptrend could mean a lot of upside for the drug development company.
With FDA planning to regulate nicotine levels, XXII (holding 200 patents protecting their production/manufaturing methods for making VLN, very low nicotine, tobacco) is well positioned to capitalize on the ~$20b of Big Tobacco market cap lost since July. In July, the FDA publicly announced their ambitions to change tobacco regulation. In addition, the FDA has ...